파로스백신

Characteristics of CTL therapy

The traditional induction and proliferation of cytotoxic T lymphocytes (CTL) requires the use of separate antigen-presenting cells such as B cells transformed by EBV or dendritic cells or recombinant viruses to impart antigen specificity, which is restricted to histocompatibility antigen (HLA), requires high costs, and has long-term culture periods. To resolve these problems, Pharos Vaccine has used recombinant overlapping peptides, which has been mainly used for exploring the immunodominant epitope of immune cells, as an antigen to develop an innovative CTL in vitro culture and proliferation methods.

The CTL therapy of Pharos Vaccine involves the efficient proliferation of virus-specific T cells in the peripheral blood using viral antigen peptides, IL-2, and anti-CD3 antibodies and injection into the patient’s body to prevent and treat infectious diseases after hematopoietic stem cell transplantation.

Also, to prevent reactivation of virus and disease progression in patients with chronic hepatitis B or hepatitis B-derived hepatic cancer, we are developing CTL therapeutics using dendritic cells to culture HBV-specific T cells and injecting them into the patient’s body.